Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

BACKGROUND: Antibodies targeting the programmed death‐ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) checkpoint may cause adverse events (AEs) that are linked to the mechanism of action of this therapeutic class and unique from those observed with conventional chemotherapy. METHODS: Patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Kelly, Karen, Infante, Jeffrey R., Taylor, Matthew H., Patel, Manish R., Wong, Deborah J., Iannotti, Nicholas, Mehnert, Janice M., Loos, Anja H., Koch, Helga, Speit, Isabell, Gulley, James L.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947549/
https://ncbi.nlm.nih.gov/pubmed/29469949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31293
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados